Core Insights - CalciMedica, Inc. has appointed Stephen Bardin as Chief Financial Officer, succeeding Daniel Geffken, who will depart after the third quarter financial statements are filed [1][2] - Bardin has extensive experience in capital raising and corporate development, having previously served as CFO at atai Life Sciences and BridgeBio Pharma, where he helped raise over $2 billion [2][3] - The company is focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases, with promising clinical data from recent trials [3] Company Developments - CalciMedica's lead product candidate, Auxora™, has shown positive results in multiple clinical trials, including a Phase 2b trial in acute pancreatitis and a Phase 2 trial in COVID pneumonia [3] - The company is currently conducting a Phase 2 trial (KOURAGE) in acute kidney injury, with data expected in 2025, and is also supporting a Phase 1/2 trial in asparaginase-induced pancreatic toxicity [3] - The recent appointment of Bardin is expected to enhance the company's strategic direction and financial operations as it advances its clinical-stage pipeline [2][3]
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer